Literature DB >> 1832452

Interleukin-2, interleukin-2 receptor and interleukin-4 levels are elevated in the sera of patients with periodontal disease.

C G McFarlane1, M C Meikle.   

Abstract

Three serological markers of immune cell activation, interleukin-2 (IL-2), soluble interleukin-2 receptor (sIL-2R), and interleukin-4 (IL-4), were measured by enzyme-linked immunosorbent assays in 20 control subjects and 26 periodontitis patients. The experimental group comprised 19 juvenile/post-juvenile and 7 severe generalized periodontitis patients with radiographic evidence of alveolar bone loss. Although some control sera contained immunoreactive IL-2 (2 of 20) and IL-4 (3 of 20), all contained sIL-2R, the levels of which correlated well with age (r = 0.644). Mean levels of all three markers were significantly elevated in the sera of patients with periodontal disease compared to control values. However, there was a wide variation in the amounts detected; IL-2 (0.21-173.33 ng/ml); sIL-2R (217.95-1177.27 units/ml); IL-4 (3.17-16.35 pg/ml), which did not correlate with either the degree of bone loss or pocket formation observed clinically. Moreover, there was no correlation between the levels of IL-2, sIL-2R or IL-4 for any given individual in the experimental group. The finding that only 2 of the control sera contained IL-2 (10%) compared to 23 of the periodontitis patients (88.5%) suggests that, of the three parameters investigated, the measurement of IL-2 could provide a sensitive laboratory test for assessing periodontal disease activity. Nevertheless, a definitive study to determine the relationship of serum IL-2 levels to clinical parameters of disease activity will be necessary to confirm this observation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832452     DOI: 10.1111/j.1600-0765.1991.tb01729.x

Source DB:  PubMed          Journal:  J Periodontal Res        ISSN: 0022-3484            Impact factor:   4.419


  8 in total

1.  Maternal periodontitis treatment and child neurodevelopment at 24 to 28 months of age.

Authors:  Bryan S Michalowicz; James S Hodges; Richard C Lussky; Henrietta Bada; Twila Rawson; L Susan Buttross; Claudia Chiriboga; Anthony J Diangelis; M John Novak; William Buchanan; Dennis A Mitchell; Panos N Papapanou
Journal:  Pediatrics       Date:  2011-04-11       Impact factor: 7.124

2.  Ursolic acid inhibits T-cell activation through modulating nuclear factor-κ B signaling.

Authors:  Guang Zeng; Jiang Chen; Qing-Hua Liang; Wan-Hui You; Han-Jun Wu; Xin-Gui Xiong
Journal:  Chin J Integr Med       Date:  2011-10-12       Impact factor: 1.978

3.  Antigen-presenting properties of gingival fibroblasts in chronic adult periodontitis.

Authors:  A Wassenaar; A Snijders; L Abraham-Inpijn; M L Kapsenberg; F Kievits
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

4.  CD26 Immuno-Expression and Periodontal Disease Progression.

Authors:  P. M. L. Manna; J. E. Costa; R. S. Gomez
Journal:  J Biomed Biotechnol       Date:  2001

5.  Association of interleukin-4 and interleukin-17F polymorphisms in periodontitis in Dravidian ethnicity.

Authors:  Nidhi Jain; Rosamma Joseph; Shabeesh Balan; R Arun; Moinak Banerjee
Journal:  Indian J Hum Genet       Date:  2013-01

6.  Gene polymorphism and protein of human pro- and anti-inflammatory cytokines in Chinese healthy subjects and chronic periodontitis patients.

Authors:  Wings T Y Loo; Chang-bin Fan; Lan-jun Bai; Yuan Yue; Yi-ding Dou; Min Wang; Hao Liang; Mary N B Cheung; Louis W C Chow; Jin-le Li; Ye Tian; Liu Qing
Journal:  J Transl Med       Date:  2012-09-19       Impact factor: 5.531

7.  Association between Polymorphisms in Interleukins 4 and 13 Genes and Chronic Periodontitis in a Han Chinese Population.

Authors:  Dong Chen; Tian-Liang Zhang; Xia Wang
Journal:  Biomed Res Int       Date:  2016-04-18       Impact factor: 3.411

8.  A Systematic Review and Meta-Analysis on Multiple Cytokine Gene Polymorphisms in the Pathogenesis of Periodontitis.

Authors:  Xin Liu; Hui Li
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.